Contract facts
UnrestrictedGRANT SEQIRUS 15-DAY NO COST EXTENSION TO COMPLETE FINAL REPORT. is a federal Unrestricted award for Barda - Aspr / Daappo / Barda Dcma held by Seqirus Inc. Estimated value —. Related solicitation 17100SOL00007.
GRANT SEQIRUS 15-DAY NO COST EXTENSION TO COMPLETE FINAL REPORT.
Want the durability read on 75A50118D00004? One Pursuit Analysis, $500, inside 48 business hours.
- 48 business hours
- $500
- Credits toward the Pack
Incumbent footprint
Public recordSeqirus Inc — $419.6M obligated across 33 awards (firm-wide, all agencies).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 75A50118D00004?
75A50118D00004 (GRANT seqirus 15-day NO COST extension) is a Barda - Aspr / Daappo / Barda Dcma award with an estimated value of —, currently held by Seqirus Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded 75A50118D00004?
Barda - Aspr / Daappo / Barda Dcma awarded 75A50118D00004 to Seqirus Inc.
Who is the incumbent on 75A50118D00004?
Seqirus Inc is the incumbent with $419.6M across 33 related awards in SCOUT’s public footprint.
When does Seqirus Inc’s 75A50118D00004 come up for recompete?
SCOUT tracks a period-of-performance end of an unstated date. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Want the durability read on 75A50118D00004? One Pursuit Analysis, $500, inside 48 business hours.
One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.
No card · under a minute · then the Sprint menu
Buy one Pursuit Analysis — $500Credits toward the Sprint Pack
Compare plansData: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.